JP2014508748A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014508748A5 JP2014508748A5 JP2013553501A JP2013553501A JP2014508748A5 JP 2014508748 A5 JP2014508748 A5 JP 2014508748A5 JP 2013553501 A JP2013553501 A JP 2013553501A JP 2013553501 A JP2013553501 A JP 2013553501A JP 2014508748 A5 JP2014508748 A5 JP 2014508748A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- binding fragment
- antibody
- alpha toxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims 31
- 239000000427 antigen Substances 0.000 claims 29
- 108091007433 antigens Proteins 0.000 claims 29
- 102000036639 antigens Human genes 0.000 claims 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 101710092462 Alpha-hemolysin Proteins 0.000 claims 9
- 101710197219 Alpha-toxin Proteins 0.000 claims 9
- 101710124951 Phospholipase C Proteins 0.000 claims 9
- 239000002776 alpha toxin Substances 0.000 claims 9
- 108010092231 staphylococcal alpha-toxin Proteins 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 206010035664 Pneumonia Diseases 0.000 claims 3
- 230000003115 biocidal effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010040872 skin infection Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010018910 Haemolysis Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000006037 cell lysis Effects 0.000 claims 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 claims 1
- 230000001461 cytolytic effect Effects 0.000 claims 1
- 230000008588 hemolysis Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161440581P | 2011-02-08 | 2011-02-08 | |
| US61/440,581 | 2011-02-08 | ||
| PCT/US2012/024201 WO2012109285A2 (en) | 2011-02-08 | 2012-02-07 | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017023905A Division JP6367393B2 (ja) | 2011-02-08 | 2017-02-13 | 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014508748A JP2014508748A (ja) | 2014-04-10 |
| JP2014508748A5 true JP2014508748A5 (cg-RX-API-DMAC7.html) | 2015-03-26 |
Family
ID=46639171
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553501A Pending JP2014508748A (ja) | 2011-02-08 | 2012-02-07 | 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法 |
| JP2017023905A Active JP6367393B2 (ja) | 2011-02-08 | 2017-02-13 | 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法 |
| JP2018127340A Active JP6723293B2 (ja) | 2011-02-08 | 2018-07-04 | 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法 |
| JP2020108083A Active JP7047017B2 (ja) | 2011-02-08 | 2020-06-23 | 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017023905A Active JP6367393B2 (ja) | 2011-02-08 | 2017-02-13 | 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法 |
| JP2018127340A Active JP6723293B2 (ja) | 2011-02-08 | 2018-07-04 | 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法 |
| JP2020108083A Active JP7047017B2 (ja) | 2011-02-08 | 2020-06-23 | 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法 |
Country Status (24)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2718320T3 (pl) | 2011-06-10 | 2018-06-29 | Medimmune Limited | Cząsteczki wiążące przeciwko PSL Pseudomonas i ich zastosowanie |
| KR102184343B1 (ko) * | 2011-11-07 | 2020-11-30 | 메디뮨 엘엘씨 | 항슈도모나스 ｐｓｌ 및 ｐｃｒｖ 결합 분자를 이용한 병용 요법 |
| WO2013096948A1 (en) | 2011-12-23 | 2013-06-27 | Lydon Nicholas B | Immunoglobulins and variants directed against pathogenic microbes |
| US9988439B2 (en) | 2011-12-23 | 2018-06-05 | Nicholas B. Lydon | Immunoglobulins and variants directed against pathogenic microbes |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| SG11201502937PA (en) * | 2012-11-06 | 2015-06-29 | Medimmune Llc | COMBINATION THERAPIES USING ANTI-<i>PSEUDOMONAS</i> PSL AND PCRV BINDING MOLECULES |
| CA2890385C (en) * | 2012-11-06 | 2022-07-12 | Medimmune, Llc | Methods of treating s. aureus-associated diseases |
| SG11201503232TA (en) * | 2012-11-06 | 2015-05-28 | Medimmune Llc | Antibodies to s. aureus surface determinants |
| WO2015055814A1 (en) * | 2013-10-17 | 2015-04-23 | Arsanis Biosciences Gmbh | Cross-reactive staphylococcus aureus antibody sequences |
| WO2015109012A1 (en) | 2014-01-14 | 2015-07-23 | Integrated Biotherapeutics, Inc. | Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| TWI719938B (zh) * | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| US20180017559A1 (en) * | 2014-08-12 | 2018-01-18 | Arsanis Biosciences Gmbh | Predicting s. aureus disease |
| LT3699198T (lt) | 2014-11-17 | 2025-05-12 | Regeneron Pharmaceuticals, Inc. | Būdai navikams gydyti naudojant cd3×cd20 bispecifinį antikūną |
| JP6889701B2 (ja) | 2015-09-24 | 2021-06-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | アルファ溶血素バリアント |
| US20190077851A1 (en) * | 2015-10-30 | 2019-03-14 | Bruno Francois | Methods of using anti-alpha toxin antibody |
| TW202311284A (zh) | 2017-01-03 | 2023-03-16 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| CA3053164A1 (en) | 2017-02-09 | 2018-08-16 | Bluefin Biomedicine, Inc. | Anti-ilt3 antibodies and antibody drug conjugates |
| CN108456250B (zh) * | 2017-02-17 | 2025-11-28 | 恺兴生命科技(上海)有限公司 | 靶向il-13ra2的抗体及其应用 |
| CN109384844B (zh) * | 2017-08-04 | 2020-12-18 | 中国人民解放军军事医学科学院基础医学研究所 | 一种抗金黄色葡萄球菌α溶血素单克隆抗体及应用 |
| EP3840838A2 (en) | 2018-07-24 | 2021-06-30 | MedImmune, LLC | Antibody directed against s.aureus clumping factor a (clfa) |
| WO2020041532A1 (en) * | 2018-08-21 | 2020-02-27 | Sf17 Therapeutics, Inc. | Compositions and methods for treating progressive neurodegenerative diseases |
| FI3844189T3 (fi) | 2018-08-31 | 2025-03-05 | Regeneron Pharma | Annostusstrategia, joka lieventää bispesifisten CD3/CD20-vasta-aineiden sytokiinien vapautumisoireyhtymää |
| CN113015745B (zh) | 2018-10-09 | 2025-02-11 | 免疫医疗有限责任公司 | 针对金黄色葡萄球菌白细胞毒素的抗体 |
| JP2022512647A (ja) | 2018-10-09 | 2022-02-07 | メディミューン，エルエルシー | 抗黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）抗体の組み合わせ |
| US12264194B2 (en) | 2019-03-13 | 2025-04-01 | Medimmune, Llc | Decreasing Staphylococcus aureus infections in colonized patients |
| WO2020210650A1 (en) | 2019-04-12 | 2020-10-15 | Medimmune, Llc | Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections |
| CN112538112B (zh) * | 2019-09-20 | 2023-10-27 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其应用 |
| CN113444173A (zh) | 2020-03-25 | 2021-09-28 | 兴盟生物医药(苏州)有限公司 | 金黄色葡萄球菌α-毒素特异性抗体及其应用 |
| EP4286409A4 (en) * | 2021-01-11 | 2025-01-01 | Starmab Biologics (Suzhou) Co., Ltd | ANTIGEN-BINDING PROTEIN TARGETING STAPHYLOCOCCUS AUREUS ?-HEMOLYTIC AND RELATED APPLICATION |
| CN112941136B (zh) * | 2021-03-24 | 2023-04-28 | 成都欧林生物科技股份有限公司 | 一种重组金黄色葡萄球菌疫苗hi抗原蛋白的纯化方法 |
| CN114455048B (zh) * | 2022-03-02 | 2023-03-14 | 江苏微导纳米科技股份有限公司 | 一种桨杆 |
| WO2023208123A1 (zh) * | 2022-04-28 | 2023-11-02 | 珠海泰诺麦博制药股份有限公司 | 特异性结合金黄色葡萄球菌Hla毒素的全人源单克隆抗体 |
| CN116589566A (zh) * | 2022-11-18 | 2023-08-15 | 昆明医科大学第一附属医院 | 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用 |
| CN116023486B (zh) * | 2023-01-10 | 2024-10-08 | 西北农林科技大学 | 金黄色葡萄球菌α-溶血素纳米抗体、制备方法及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| RU2251572C2 (ru) | 1996-04-25 | 2005-05-10 | Дженикон Сайенсиз Корпорейшн, Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Анализ аналитов с использованием частиц в качестве метки |
| EP1522590B1 (en) | 2000-06-28 | 2009-08-26 | Glycofi, Inc. | Methods for producing modified glycoproteins |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US20030226155A1 (en) | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
| ES2338105T3 (es) | 2003-05-14 | 2010-05-04 | Kenta Biotech Ag | Anticuerpo monoclonal humano especifico para lipopolisacaridos (lps) de serotipo iats 06 pseudomonas aeruginosa. |
| CN1324049C (zh) | 2003-08-04 | 2007-07-04 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗sars冠状病毒基因工程抗体 |
| JP4633788B2 (ja) * | 2004-04-13 | 2011-02-16 | エフ．ホフマン−ラ ロシュ アーゲー | 抗ｐ−セレクチン抗体 |
| KR101505496B1 (ko) * | 2004-09-22 | 2015-03-25 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성 조성물 |
| WO2007084926A2 (en) | 2006-01-17 | 2007-07-26 | Biolex Therapeutics, Inc. | Compositions and methods for humanization and optimization of n-glycans in plants |
| TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
| AU2007259415B2 (en) * | 2006-06-12 | 2013-09-26 | Glaxosmithkline Biologicals Sa | Use of alpha-toxin for treating and preventing Staphylococcus infections |
| MX2009012891A (es) * | 2007-05-31 | 2009-12-10 | Merck & Co Inc | Proteinas de union a antigeno dirigidas a staphylococcus aureus orf0657n. |
| WO2009026303A1 (en) * | 2007-08-21 | 2009-02-26 | Amgen Inc. | Human c-fms antigen binding proteins |
| AU2008292897B2 (en) * | 2007-08-31 | 2015-01-22 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
| US8172115B1 (en) | 2008-04-10 | 2012-05-08 | Spencer Forrest, Inc. | Hair building solids dispenser for one handed operation |
| EA201170028A1 (ru) * | 2008-07-02 | 2011-12-30 | Эмерджент Продакт Дивелопмент Сиэтл, Ллс | СВЯЗЫВАЮЩИЕ НЕСКОЛЬКО МИШЕНЕЙ БЕЛКИ, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКИМ ДЕЙСТВИЕМ TNF-α |
| EP2208787A1 (en) * | 2009-01-19 | 2010-07-21 | Université de Liège | A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
| GB2467939A (en) * | 2009-02-20 | 2010-08-25 | Univ Sheffield | Removal of bacteria from media |
| PL2445522T3 (pl) * | 2009-06-22 | 2018-01-31 | Wyeth Llc | Kompozycje immunogenne antygenów Staphylococcus aureus |
| SG11201503232TA (en) * | 2012-11-06 | 2015-05-28 | Medimmune Llc | Antibodies to s. aureus surface determinants |
-
2012
- 2012-02-07 US US13/983,804 patent/US9527905B2/en active Active
- 2012-02-07 MX MX2017001101A patent/MX375113B/es unknown
- 2012-02-07 SG SG10201600899PA patent/SG10201600899PA/en unknown
- 2012-02-07 KR KR1020137023512A patent/KR101993839B1/ko active Active
- 2012-02-07 SG SG2013057831A patent/SG192212A1/en unknown
- 2012-02-07 CA CA2826566A patent/CA2826566C/en active Active
- 2012-02-07 CN CN201280007986.4A patent/CN103443285B9/zh active Active
- 2012-02-07 CN CN201710480750.7A patent/CN107474133B/zh active Active
- 2012-02-07 SI SI201231470T patent/SI2673373T1/sl unknown
- 2012-02-07 MX MX2013009127A patent/MX345285B/es active IP Right Grant
- 2012-02-07 TR TR2018/17932T patent/TR201817932T4/en unknown
- 2012-02-07 AU AU2012214531A patent/AU2012214531C1/en active Active
- 2012-02-07 HR HRP20182017TT patent/HRP20182017T4/hr unknown
- 2012-02-07 ES ES12745207T patent/ES2709065T7/es active Active
- 2012-02-07 RS RS20181450A patent/RS58190B2/sr unknown
- 2012-02-07 EP EP12745207.6A patent/EP2673373B3/en active Active
- 2012-02-07 PL PL12745207T patent/PL2673373T6/pl unknown
- 2012-02-07 RU RU2013141134A patent/RU2620065C2/ru active
- 2012-02-07 PT PT12745207T patent/PT2673373T/pt unknown
- 2012-02-07 WO PCT/US2012/024201 patent/WO2012109285A2/en not_active Ceased
- 2012-02-07 DK DK12745207.6T patent/DK2673373T6/da active
- 2012-02-07 BR BR112013020086-3A patent/BR112013020086B1/pt active IP Right Grant
- 2012-02-07 EP EP18190790.8A patent/EP3470526A3/en active Pending
- 2012-02-07 HU HUE12745207A patent/HUE040734T2/hu unknown
- 2012-02-07 JP JP2013553501A patent/JP2014508748A/ja active Pending
- 2012-02-07 LT LTEP12745207.6T patent/LT2673373T/lt unknown
- 2012-02-07 SM SM20180635T patent/SMT201800635T1/it unknown
- 2012-02-07 SG SG10201913690SA patent/SG10201913690SA/en unknown
-
2013
- 2013-08-07 MX MX2020009700A patent/MX2020009700A/es unknown
-
2017
- 2017-02-13 JP JP2017023905A patent/JP6367393B2/ja active Active
-
2018
- 2018-07-04 JP JP2018127340A patent/JP6723293B2/ja active Active
- 2018-11-28 CY CY20181101266T patent/CY1121389T1/el unknown
-
2020
- 2020-06-23 JP JP2020108083A patent/JP7047017B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014508748A5 (cg-RX-API-DMAC7.html) | ||
| HRP20182017T4 (hr) | Protutijela koja specifično vežu alfa toksin koji stvara staphylococcus aureus i postupci uporabe | |
| JP2020503891A5 (cg-RX-API-DMAC7.html) | ||
| JP2021063090A5 (cg-RX-API-DMAC7.html) | ||
| JP2019511911A5 (cg-RX-API-DMAC7.html) | ||
| RU2015121624A (ru) | Антитела к поверхностным детерминантам s. aureus | |
| TR201809128T4 (tr) | Gram-pozitif bakterilere spesifik bağlanan bileşikler. | |
| EP2532365A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
| JP6064241B2 (ja) | 黄色ブドウ球菌由来のα毒素に対するヒトモノクローナル抗体、及び膿瘍形成の治療又は予防におけるその使用 | |
| EP2532366A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER | |
| JP2012522010A5 (cg-RX-API-DMAC7.html) | ||
| JP2017518258A5 (cg-RX-API-DMAC7.html) | ||
| JP2017510567A5 (cg-RX-API-DMAC7.html) | ||
| RU2015143886A (ru) | Антитела к тау и способы применения | |
| JP2015536951A5 (cg-RX-API-DMAC7.html) | ||
| JP2018508483A5 (cg-RX-API-DMAC7.html) | ||
| JP2016507470A5 (cg-RX-API-DMAC7.html) | ||
| JP2018500014A5 (cg-RX-API-DMAC7.html) | ||
| RU2015121617A (ru) | Способы лечения заболеваний, ассоциированных с s. aureus | |
| RU2018117862A (ru) | Новый полипептид с аффинностью к PD-L1 | |
| SI2780368T1 (en) | INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A | |
| RU2571204C3 (ru) | Специфические связывающие агенты против в7-н1 | |
| JP2012121878A5 (cg-RX-API-DMAC7.html) | ||
| JP2013520996A5 (cg-RX-API-DMAC7.html) | ||
| JP2019510739A5 (cg-RX-API-DMAC7.html) |